Century Therapeutics (IPSC) Income towards Parent Company (2020 - 2026)

Century Therapeutics (IPSC) has reported Income towards Parent Company for 7 consecutive years, with -$90.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 218.75% year-over-year to -$90.9 million; the TTM figure through Mar 2026 stood at -$167.4 million (down 677.04% YoY), while the FY2025 annual figure was $2.1 million, up 101.64% from the prior year.
• Income towards Parent Company eased to -$90.9 million in Q1 2026 per IPSC's latest filing, from -$9.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $76.6 million in Q1 2025 and bottomed at -$90.9 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$28.5 million across 5 years, with a median of -$31.7 million in 2022.
• Annual changes were most pronounced in 2025 — Income towards Parent Company soared 372.82% — and 2026, when it plunged 218.75%.
• Century Therapeutics' Income towards Parent Company stood at -$31.7 million in 2022, then fell by 24.35% to -$39.4 million in 2023, then gained by 9.45% to -$35.7 million in 2024, then soared by 73.24% to -$9.5 million in 2025, then slumped by 852.26% to -$90.9 million in 2026.
• Business Quant data shows IPSC's Income towards Parent Company at -$90.9 million in Q1 2026, -$9.5 million in Q4 2025, and -$34.4 million in Q3 2025.